{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:38:29Z","timestamp":1777599509583,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14890-7","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:45:26Z","timestamp":1759229126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of 18F-FDG PET\/CT metabolic parameters for gastric cancer patients\u2019 microsatellite instability status"],"prefix":"10.1186","volume":"25","author":[{"given":"Bangyu","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyue","family":"Na","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kezheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"3","key":"14890_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14890_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2468-1253(19)30328-0","volume":"5","author":"Collaborators GBDSC","year":"2020","unstructured":"Collaborators GBDSC. The global, regional, and national burden of stomach cancer in 195 countries, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):42\u201354.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"14890_CR3","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1245\/s10434-009-0580-8","volume":"16","author":"E Oki","year":"2009","unstructured":"Oki E, Kakeji Y, Zhao Y, Yoshida R, Ando K, Masuda T, Ohgaki K, Morita M, Maehara Y. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol. 2009;16(9):2510\u20135.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"14890_CR4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3892\/mmr.2020.11183","volume":"22","author":"Q Wang","year":"2020","unstructured":"Wang Q, Xie Q, Liu Y, Guo H, Ren Y, Li J, Zhao Q. Clinical characteristics and prognostic significance of TCGA and ACRG classification in gastric cancer among the Chinese population. Mol Med Rep. 2020;22(2):828\u201340.","journal-title":"Mol Med Rep"},{"issue":"8","key":"14890_CR5","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H, et al. The Chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;41(8):747\u201395.","journal-title":"Cancer Commun"},{"issue":"2","key":"14890_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"14890_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-020-00774-4","volume":"21","author":"TH Patel","year":"2020","unstructured":"Patel TH, Cecchini M. Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 2020;21(9):70.","journal-title":"Curr Treat Options Oncol"},{"issue":"7517","key":"14890_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"22","key":"14890_CR9","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","volume":"7","author":"S Derks","year":"2016","unstructured":"Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, et al. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget. 2016;7(22):32925\u201332.","journal-title":"Oncotarget"},{"issue":"5","key":"14890_CR10","doi-asserted-by":"publisher","first-page":"e180013","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. 2018;4(5):e180013.","journal-title":"JAMA Oncol"},{"issue":"9","key":"14890_CR11","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","volume":"19","author":"R Sun","year":"2018","unstructured":"Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19(9):1180\u201391.","journal-title":"Lancet Oncol"},{"issue":"2","key":"14890_CR12","volume":"1","author":"M Wu","year":"2019","unstructured":"Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z. Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response. Radiology: Imaging Cancer. 2019;1(2): e190031.","journal-title":"Radiology: Imaging Cancer"},{"issue":"1","key":"14890_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-14965-6","volume":"12","author":"K Yamada","year":"2022","unstructured":"Yamada K, Urakawa N, Kanaji S, Hasegawa H, Yamamoto M, Yamashita K, Matsuda T, Oshikiri T, Suzuki S, Kakeji Y. Preoperative prediction of the pathological stage of advanced gastric cancer by (18)F-fluoro-2-deoxyglucose positron emission tomography. Sci Rep. 2022;12(1): 11370.","journal-title":"Sci Rep"},{"issue":"7","key":"14890_CR14","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/MNM.0000000000001567","volume":"43","author":"F Simionato Perrotta","year":"2022","unstructured":"Simionato Perrotta F, Ribeiro U Jr., Mester M, Sobroza de Mello E, Sado HN, Bezerra Pinheiro RB, Tustumi F, Buchpiguel CA, Zilberstein B, Sallum RAA, et al. Evaluation of the 18F-FDG-PET\/CT uptake association with pathological and immunohistochemistry features in esophagogastric adenocarcinoma. Nucl Med Commun. 2022;43(7):823\u201333.","journal-title":"Nucl Med Commun"},{"key":"14890_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.724464","volume":"12","author":"H Liu","year":"2021","unstructured":"Liu H, Ye Z, Yang T, Xie H, Duan T, Li M, Wu M, Song B. Predictive value of metabolic parameters derived from (18)F-FDG PET\/CT for microsatellite instability in patients with colorectal carcinoma. Front Immunol. 2021;12: 724464.","journal-title":"Front Immunol"},{"issue":"1","key":"14890_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","volume":"52","author":"HJ Im","year":"2018","unstructured":"Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better?? Nucl Med Mol Imaging. 2018;52(1):5\u201315.","journal-title":"Nucl Med Mol Imaging"},{"issue":"11","key":"14890_CR17","first-page":"2989","volume":"18","author":"K Debiec","year":"2017","unstructured":"Debiec K, Wydmanski J, Gorczewska I, Leszczynska P, Gorczewski K, Leszczynski W, d\u2019Amico A, Kalemba M. 18-fluorodeoxy-glucose positron emission tomography- computed tomography (18-FDG-PET\/CT) for gross tumor volume (GTV) delineation in gastric cancer radiotherapy. Asian Pac J Cancer Prev. 2017;18(11):2989\u201398.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"14890_CR18","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4274\/mirt.galenos.2021.78055","volume":"30","author":"SA Erturk","year":"2021","unstructured":"Erturk SA, Hasbek Z, Ozer H. The relationship between HER-2 expression levels and (18)F-FDG PET\/CT parameters in gastric cancer. Mol Imaging Radionucl Ther. 2021;30(3):150\u20137.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"3","key":"14890_CR19","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837\u201345.","journal-title":"Biometrics"},{"issue":"2","key":"14890_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10120-017-0739-0","volume":"21","author":"JS Park","year":"2018","unstructured":"Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M. The prognostic value of volume-based parameters using (18)F-FDG PET\/CT in gastric cancer according to HER2 status. Gastric Cancer. 2018;21(2):213\u201324.","journal-title":"Gastric Cancer"},{"issue":"2","key":"14890_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00259-014-2903-7","volume":"42","author":"HJ Im","year":"2015","unstructured":"Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Chung JK, Kim EE, Lee DS. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging. 2015;42(2):241\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"14890_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12149-012-0604-5","volume":"26","author":"PB Romesser","year":"2012","unstructured":"Romesser PB, Qureshi MM, Shah BA, Chatburn LT, Jalisi S, Devaiah AK, Subramaniam RM, Truong MT. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET\/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med. 2012;26(7):527\u201334.","journal-title":"Ann Nucl Med"},{"issue":"5","key":"14890_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00259-016-3577-0","volume":"44","author":"Y Lim","year":"2017","unstructured":"Lim Y, Bang JI, Han SW, Paeng JC, Lee KH, Kim JH, Kang GH, Jeong SY, Park KJ, Kim TY. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. Eur J Nucl Med Mol Imaging. 2017;44(5):757\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"14890_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3348\/kjr.2013.14.1.1","volume":"14","author":"SH Moon","year":"2013","unstructured":"Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol. 2013;14(1):1\u201312.","journal-title":"Korean J Radiol"},{"issue":"1","key":"14890_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13139-013-0260-2","volume":"48","author":"MK Rahim","year":"2014","unstructured":"Rahim MK, Kim SE, So H, Kim HJ, Cheon GJ, Lee ES, Kang KW, Lee DS. Recent trends in PET image interpretations using volumetric and texture-based quantification methods in nuclear oncology. Nucl Med Mol Imaging. 2014;48(1):1\u201315.","journal-title":"Nucl Med Mol Imaging"},{"issue":"2","key":"14890_CR26","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10120-012-0165-2","volume":"16","author":"HW Chung","year":"2013","unstructured":"Chung HW, Lee SY, Han HS, Park HS, Yang JH, Lee HH, So Y. Gastric cancers with microsatellite instability exhibit high fluorodeoxyglucose uptake on positron emission tomography. Gastric Cancer. 2013;16(2):185\u201392.","journal-title":"Gastric Cancer"},{"issue":"2","key":"14890_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/14737140.2021.1851201","volume":"21","author":"MT Roth","year":"2021","unstructured":"Roth MT, Das S. Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy. Expert Rev Anticancer Ther. 2021;21(2):229\u201338.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"14890_CR28","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1097\/MNM.0000000000001481","volume":"42","author":"F Dondi","year":"2021","unstructured":"Dondi F, Albano D, Giubbini R, Bertagna F. 18F-FDG PET and PET\/CT for the evaluation of gastric signet ring cell carcinoma: a systematic review. Nucl Med Commun. 2021;42(12):1293\u2013300.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"14890_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1089\/gtmb.2020.0146","volume":"25","author":"JP Nshizirungu","year":"2021","unstructured":"Nshizirungu JP, Bennis S, Mellouki I, Benajah DA, Lahmidani N, El Bouhaddoutti H, Ibn Majdoub K, Ibrahimi SA, Pires Celeiro S, Viana-Pereira M, et al. Microsatellite instability analysis in gastric carcinomas of Moroccan patients. Genet Test Mol Biomarkers. 2021;25(2):116\u201323.","journal-title":"Genet Test Mol Biomarkers"},{"key":"14890_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.712760","volume":"11","author":"WL Guan","year":"2021","unstructured":"Guan WL, Ma Y, Cui YH, Liu TS, Zhang YQ, Zhou ZW, Xu JY, Yang LQ, Li JY, Sun YT, et al. The impact of mismatch repair status on prognosis of patients with gastric cancer: a multicenter analysis. Front Oncol. 2021;11: 712760.","journal-title":"Front Oncol"},{"issue":"3","key":"14890_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/bjc.2015.213","volume":"113","author":"L De Smedt","year":"2015","unstructured":"De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M, Matthijs G, et al. Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis. Br J Cancer. 2015;113(3):500\u20139.","journal-title":"Br J Cancer"},{"issue":"10","key":"14890_CR32","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1097\/RLU.0000000000001332","volume":"41","author":"Y Suzuki","year":"2016","unstructured":"Suzuki Y, Okabayashi K, Hasegawa H, Tsuruta M, Shigeta K, Murakami K, Kitagawa Y. Metabolic tumor volume and total lesion glycolysis in PET\/CT correlate with the pathological findings of colorectal cancer and allow its accurate staging. Clin Nucl Med. 2016;41(10):761\u20135.","journal-title":"Clin Nucl Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14890-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:30:23Z","timestamp":1759275023000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14890-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14890"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14890-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committees of the Harbin Medical University Cancer Hospital (2021-198-JS). The requirement for informed consent was waived by the Ethics Committee of Harbin Medical University Cancer Hospital because of the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1457"}}